Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Elektrofi is raising $42,535,095.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chase Coffman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elektrofi

Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the companys founding team of MIT engineers and scientists are shaping the future of biologics delivery.

To learn more about Elektrofi, visit http://www.elektrofi.com/

Contact:
Chase Coffman, Chief Executive Officer
866-610-2683
chase@elektrofi.com
https://www.linkedin.com/in/chase-coffman-65772b41/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved